See the results

SEE THE RESULTS

BRIUMVI was tested alongside another treatment (teriflunomide*) in more than 1,000 people with relapsing multiple sclerosis (RMS) in 2 separate, 2-year clinical studies.

SEE THE RESULTS

BRIUMVI was tested alongside another treatment (teriflunomide*) in more than 1,000 people with relapsing multiple sclerosis (RMS) in 2 separate, 2-year clinical studies.

SEE THE RESULTS

 

BRIUMVI was tested alongside another treatment (teriflunomide*) in more than 1,000 people with relapsing multiple sclerosis (RMS) in 2 separate, 2-year clinical studies.

Woman wearing blazer smiling at outside table

BRIUMVI has been proven effective in 2 clinical studies

The results from 543 people treated with BRIUMVI compared to 546 treated with teriflunomide showed that BRIUMVI was proven superior to teriflunomide at reducing relapses and significantly reducing brain lesions on magnetic resonance imaging (MRI).

BRIUMVI was proven to reduce relapses

STUDY 1

Inverted triangle image

59%

FEWER RELAPSES
with BRIUMVI compared to teriflunomide

Study 1: ARR was 0.076 for BRIUMVI vs 0.188 for teriflunomide

STUDY 2

Inverted triangle image

49%

FEWER RELAPSES
with BRIUMVI compared to teriflunomide

Study 2: ARR was 0.091 for BRIUMVI vs 0.178 for teriflunomide

BRIUMVI showed near-complete suppression of brain lesions

STUDY 1

Inverted triangle image

97%

FEWER T1 Gd+ LESIONS
with BRIUMVI (0.016) compared to teriflunomide (0.491)
on average per MRI over 2 years

STUDY 2

Inverted triangle image

97%

FEWER T1 Gd+ LESIONS
with BRIUMVI (0.009) compared to teriflunomide (0.250)
on average per MRI over 2 years

STUDY 1

Inverted triangle image

92%

FEWER T2 LESIONS
with BRIUMVI (0.213) compared to teriflunomide (2.789) on average per MRI over 2 years

STUDY 2

Inverted triangle image

90%

FEWER T2 LESIONS
with BRIUMVI (0.282) compared to teriflunomide (2.831) on average per MRI over 2 years

MORE PEOPLE TAKING BRIUMVI HAD ZERO RELAPSES

STUDY 1

Inverted triangle image

86%

of people taking BRIUMVI had ZERO RELAPSES compared to 74% for teriflunomide

STUDY 2

Inverted triangle image

87%

of people taking BRIUMVI had ZERO RELAPSES compared to 72% for teriflunomide

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.
ARR, Annualized Relapse Rate; T1 Gd+, gadolinium-enhancing lesions on T1-weighted MRI.

People included in the clinical studies:

  • More than 1,000 people (543 treated with BRIUMVI, 546 treated with teriflunomide)
  • 18–55 years of age
  • People included in the studies had greater than or equal to 1 relapse within the prior year, or greater than or equal to 2 relapses in prior 2 years, and/or greater than or equal to 1 gadolinium-enhanced T1 magnetic resonance imaging lesion in the prior year

This is important because BRIUMVI was studied in:

  • A large number of people with RMS
  • A wide age range of people with RMS
  • People who had active disease

Learn about the common side effects
of BRIUMVI

Understanding Safety

What to expect on your BRIUMVI
infusion day

Infusion Experience

JOIN THE THOUSANDS WHO ARE TAKING ON RMS WITH BRIUMVI

 

Discover how BRIUMVI is impacting real people with RMS.
Hear from people who have included it in their RMS treatment journey.

Learn More
Three people sitting and laughing around a table outdoors

JOIN THE THOUSANDS WHO ARE TAKING ON RMS WITH BRIUMVI

Three people sitting and laughing around a table outdoors

Discover how BRIUMVI is impacting real people with RMS.
Hear from people who have included it in their RMS treatment journey.

Learn More

JOIN THE THOUSANDS WHO ARE TAKING ON RMS WITH BRIUMVI

 

Discover how BRIUMVI is impacting real people with RMS.
Hear from people who have included it in their RMS treatment journey.

Learn More
Three people sitting and laughing around a table outdoors

People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time.

INDICATION AND IMPORTANT
SAFETY INFORMATION

Who should not receive BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

What is the most important information I should know
about BRIUMVI?

BRIUMVI can cause serious side effects, including:

Infusion reactions: Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:

  • fever
  • chills
  • headache
  • flu-like symptoms
  • fast heartbeat
  • hives
  • itchy skin
  • dizziness
  • feeling faint
  • swelling of tongue or throat
  • trouble breathing
  • wheezing
  • nausea
  • abdominal pain
  • throat irritation
  • redness of the face or skin

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
    • Weakened immune system: BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
    • Progressive Multifocal Leukoencephalopathy (PML): PML may happen with BRIUMVI. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
  • Low immunoglobulins: BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection.
  • take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have had a recent vaccination or are scheduled to receive any vaccinations.
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with BRIUMVI. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with BRIUMVI. If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
    • If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby’s healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. BRIUMVI may harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
  • are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BRIUMVI?

The most common side effects of BRIUMVI include:

Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to TG Therapeutics at 1-877-TGTXINC (1-877-848-9462).

For more important information, go to www.briumvi.com or call 1-833-BRIUMVI (1-833-274-8684).

Indication

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

STAY IN THE KNOW

Sign up to receive the latest updates and resources for BRIUMVI

Sign up

Join us for a Multiple Sclerosis (MS) educational event near you

Register now
Important Safety Information
Who should not receive BRIUMVI?
  • Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.
  • Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI.
 Indication
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION